A Biotech Manager's Handbook: A Practical GuideM O'Neill, M M Hopkins Elsevier, 2012 M05 2 - 414 páginas A biotech manager's handbook lays out - in a simple, straightforward manner - for the manager or would-be entrepreneur the basic principles of running a biotech company. Most managers in biotechnology companies are working in their first company or in their first managerial role. Their expertise and experience in the scientific part of the work can be taken as a given but there is a whole range of other skills to be learned and areas of expertise to come to terms with. Small companies do not have big budgets to hire people or time to become an expert in so many areas. The book starts by outlining the state of the biopharmaceutical industry and goes on to explain the importance of planning (no matter what the size of the company). Succeeding chapters deal with the basics of intellectual property, perspectives from a university technology transfer office and how to raise some initial funding from an investor and entrepreneur.
|
Contenido
1 | |
23 | |
3 Leadership and you | 55 |
4 Managing self situations and stress | 79 |
5 Its all in the plan | 105 |
6 Exploring funding routes for therapeutics firms | 131 |
7 Raising funds and managing finances | 157 |
8 Introduction to intellectual property | 179 |
why and how | 209 |
10 Successful registration of new therapies in the EU and USA | 245 |
design and practice | 283 |
starting out | 309 |
to the deal and beyond | 341 |
14 Conclusions and final thoughts | 359 |
369 | |
Otras ediciones - Ver todas
A Biotech Manager's Handbook: A Practical Guide M. O'Neill,M. M. Hopkins Sin vista previa disponible - 2017 |
A Biotech Manager's Handbook: A Practical Guide M O'Neill,M M Hopkins Sin vista previa disponible - 2012 |
Términos y frases comunes
academic activity approval assay assess biotech companies biotechnology business angels business development business plan cash flow chapter clinical development clinical trials commercial commercialisation company’s compound cost deal disease dose drug development drug discovery due diligence early-stage effect efficacy enantiomer ensure entrepreneur essential European Medicines Agency European Patent Office example experience forecast goals highly important industry innovation intellectual property investment investors involved issues licensing look major management team medicines meeting Michael O’Neill milestones million opportunity organisation orphan diseases orphan drugs partner patent application person pharma pharmaceutical pharmacokinetics pharmacovigilance phase potential preclinical prior art problems programme regulatory risk role safety scientific scientists small companies stage strategy studies successful target technical testing therapeutics firms treatment venture venture capital vitro vivo volunteers